"This noise attenuation technology is so important for infants in the NICU. The literature indicates that levels of noise found in these care areas can have short- and long-term health consequences. The American Academy of Pediatrics' guidelines are very rigorous," said George Hutchinson, Invictus Medical's Chief Technology Officer.

"This technology actively attenuates noise in incubators while allowing the parents to still converse with their babies. This is so important for language skill development."

The NSF Phase II grant provides funding of about $735,000 to complete the development of the noise attenuation technology, a process anticipated to be completed in 2018.

 Invictus states that it has assembled a set of world-renowned experts in the field of active noise attenuation to assist in this effort.

"The impact this product is going to have on the health of preterm infants in the NICU and on their cognitive development is very important," said Dennis Kane, Invictus Medical's CEO. "Invictus is committed to help this vulnerable population and we're gratified that the NSF saw the potential this represents."

Invictus Medical is a San Antonio, Texas–based medical device company that aims to ensure that children are able to attain their developmental milestones.

As evidenced by their award-winning innovations, Invictus Medical has been at the forefront of pediatric care since its founding in 2012.